UPDATE: Noble Financial Starts Peregrine Pharmaceuticals (PPHM) at Buy; Positive on Phosphatidylserine Potential

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DGNX

Go back to UPDATE: Noble Financial Starts Peregrine Pharmaceuticals (PPHM) at Buy; Positive on Phosphatidylserine Potential

Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments

July 14, 2015 4:05 PM EDT

-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015

-- Initiation of Later-Stage Bavituximab Trials to Expand Commercial Potential in NSCLC and Breast Cancer Planned for Second Half of Calendar Year 2015 --

-- Avids Contract Manufacturing Revenue Exceeds $26 Million for Fiscal Year 2015

TUSTIN, Calif., July 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on developing novel investigational products that... More